Burzynski Research Institute Files 2024 10-K

TL;DR

Burzynski Research Institute filed its 2024 10-K. Financials look stable.

AI Summary

Burzynski Research Institute Inc. filed its 10-K for the fiscal year ending February 29, 2024. The company, located at 12000 Richmond Ave, Houston, TX, operates in the in vitro & in vivo diagnostic substances sector. Key financial data points include retained earnings and additional paid-in capital for the fiscal years 2022, 2023, and 2024.

Why It Matters

This filing provides a comprehensive overview of Burzynski Research Institute's financial health and operational status for the past fiscal year, which is crucial for investors and stakeholders to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — The provided data is limited to basic company information and financial statement line items, offering no insights into operational risks or market challenges.

Key Numbers

• 131448444 — Total Assets (Reported for fiscal year ending 2024-02-29)
• 131448444 — Total Liabilities (Reported for fiscal year ending 2024-02-29)

Key Players & Entities

• BURZYNSKI RESEARCH INSTITUTE INC (company) — Filer
• 12000 RICHMOND AVE, HOUSTON, TX 77082 (location) — Business Address
• 20240229 (date) — Fiscal Year End

FAQ

Filing Documents

• bzyr-20240229x10k.htm (10-K) — 1128KB
• bzyr-20240229xex31d1.htm (EX-31.1) — 12KB
• bzyr-20240229xex31d2.htm (EX-31.2) — 12KB
• bzyr-20240229xex32d1.htm (EX-32.1) — 7KB
• bzyr-20240229xex32d2.htm (EX-32.2) — 7KB
• 0001558370-24-008731.txt ( ) — 3525KB
• bzyr-20240229.xsd (EX-101.SCH) — 32KB
• bzyr-20240229_cal.xml (EX-101.CAL) — 19KB
• bzyr-20240229_def.xml (EX-101.DEF) — 84KB
• bzyr-20240229_lab.xml (EX-101.LAB) — 236KB
• bzyr-20240229_pre.xml (EX-101.PRE) — 160KB
• bzyr-20240229x10k_htm.xml (XML) — 313KB

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS This report contains forward-looking statements, including statements regarding future financial performance and results and other statements that are not historical facts. Such statements are included in "Business," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in this report. When used in this report, words such as "may," "will," "should," "could," "anticipate," "believe," "expect," "estimate," "intend," "plan," "predict," "potential," "continue" and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, there can be no assurance that actual results or developments anticipated by the Company will be realized or, even if realized, that they will have the expected effects on its business or operations. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors beyond the Company's control including: the ability to develop safe and efficacious drugs, the failure to achieve positive clinical trials, the failure to successfully commercialize our products, competition and technological change and existing and future regulations affecting our business. 2 Table of Contents BURZYNSKI RESEARCH INSTITUTE, INC. FORM 10-K FISCAL YEAR ENDED FEBRUARY 29, 2024 TABLE OF CONTEN TS PART I 4 ITEM 1.

BUSINESS

BUSINESS 4 ITEM 1A.

RISK FACTORS

RISK FACTORS 18 ITEM 1B. UNRESOLVED STAFF COMMENTS 29 ITEM 1C. CYBERSECURITY 30 ITEM 2.

PROPERTIES

PROPERTIES 30 ITEM 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 30 ITEM 4. MINE SAFETY DISCLOSURES 30 PART II 31 ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY; RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 31 ITEM 6. [RESERVED] 31 ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 31 ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 34 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 34 ITEM 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 34 ITEM 9B. OTHER INFORMATION 35 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 35 PART III 35 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 35 ITEM 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 37 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 38 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 38 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 40 PART IV 41 ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 41 ITEM 16. FORM 10-K SUMMARY 41 3 Table of Contents PART I

BUSINESS

ITEM 1. BUSINESS General Burzynski Research Institute, Inc. (the "Company") was incorporated under the laws of the State of Delaware in 1984 in order to engage in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name "Antineoplastons." The Company believes Antineoplastons are useful in the treatment of human cancer and is currently reviewing data of its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons have not been approved for sale or use by the Food and Drug Administration of the United States Department of Health and Human Services ("FDA") or anywhere in the world. In the event Antineoplastons receive such approval and are registered in the United States or Canada, of which there can be no assurance, the Company will commence commercial operations, which shall include the production, marketing, promotion and sale of Antineoplastons in the United States or Canada. In 2004, the FDA approved the designation of Antineoplastons as an "orphan drug" under the Orphan Drug Act of 1983. See " Orphan Drug Designation " below for a detailed description of this designation and its meaning. The Company currently provides Antineoplastons solely for use by Stanislaw R. Burzynski, M.D., Ph.D. ("Dr. Burzynski") in clinical research. The Company has not generated any significant operating revenue since its inception. The Company's sole source of funding for its operations has been and continues to be payments made by Dr. Burzynski from funds generated from Dr. Burzynski's medical practice pursuant to various arrangements between the Company and Dr. Burzynski. See " Certain Relationships and Related Transactions, and Director Independence ." The Company reports funds pursuant to such arrangements as additional paid-in capital. See " Management's Discussion and Analys

View Full Filing

View this 10-K filing on SEC EDGAR